ID | 118363 |
Title Alternative | Vedolizumab for pediatric IBD
|
Author |
Fukura, Shoko
Tokushima Prefectural Central Hospital
Takei, Mikiko
Tokushima Prefectural Central Hospital|Tokushima Municipal Hospital
Takeuchi, Shunsuke
Tokushima Prefectural Central Hospital
Tayama, Takahiro
Tokushima Prefectural Central Hospital
Ono, Akemi
Tokushima Prefectural Central Hospital
Ichihara, Yuko
Tokushima Prefectural Central Hospital
Shichijo, Koichi
Tokushima Prefectural Central Hospital
Suzuki, Yasuhiro
Tokushima Prefectural Central Hospital
Mori, Kazuhiro
Tokushima Prefectural Central Hospital
|
Keywords | Ulcerative colitis
Inflammatory bowel disease
Vedolizumab
Infliximab
Pediatric IBD
|
Content Type |
Journal Article
|
Description | Pediatric ulcerative colitis is likely to be more severe than adult ulcerative colitis. Failure to thrive should be considered during therapy. A 10-year-old boy was diagnosed with ulcerative colitis based on his clinical presentation and colonoscopy and biopsy results. The administration of 5-aminosalicylic acid and prednisolone resulted in remission ; however, the symptoms reappeared after the discontinuation of prednisolone. Then, infliximab was administered ; however, the patient was resistant to it and appeared to be dependent on prednisolone. Vedolizumab, a monoclonal antibody against α4β7 integrin, was administered, which resulted in rapid remission. A steady decrease in prednisolone followed, and remission was maintained even after prednisolone discontinuation. Vedolizumab may be effective in pediatric patients with moderate-to-severe refractory ulcerative colitis. Vedolizumab prevents lymphocytes from binding to MAdCAM-1, which is selectively expressed in the gastrointestinal submucosa, leading to the mitigation of the systemic side effects of immunosuppression, such as infections. In Japan, vedolizumab use is not yet approved for use in children, but its effectiveness and safety in children is expected to be investigated in the future.
|
Journal Title |
The Journal of Medical Investigation
|
ISSN | 13496867
13431420
|
NCID | AA11166929
|
Publisher | Tokushima University Faculty of Medicine
|
Volume | 70
|
Issue | 1-2
|
Start Page | 294
|
End Page | 297
|
Sort Key | 294
|
Published Date | 2023-02
|
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
University Hospital
Medical Sciences
|